

Clinical trials of combination

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
combination vs placebo			
PHS II (multivitamin) , 2012 [NCT00270647] n=7317/7324 follow-up: 11.2y (median)	Daily multivitamin versus placebo	male US physicians initially aged 50 years or older	Parallel groups double-blind USA
POPADAD (antioxydant) , 2008 [ISRCTN53295293] n=640/636 follow-up:	antioxidant capsule containing (alpha-tocopherol 200 mg, ascorbic acid 100 mg, pyridoxine hydrochloride 25 mg, zinc sulphate 10 mg, nicotinamide 10 mg, lecithin 9.4 mg, and sodium selenite 0.8 mg) versus placebo	patients with diabetes mellitus and asymptomatic peripheral arterial disease	Factorial plan double blind Scotland
HATS , 2001 n=84/76 follow-up:	antioxidant-therapy (vitamins) versus placebo	patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol	Factorial plan double-blind USA, Canada
MVP , 1997 n=158/159 follow-up: 6 montsh	multivitamins (30,000 IU of beta carotene, 500 mg of vitamin C, and 700 IU of vitamin E) for four weeks before and six months after angioplasty versus placebo	patient undergoing angioplasty	Factorial plan double-blind Canada
HPS antioxidant , 2002 n=10269/10267 follow-up: jul 1994 - may 1997	antioxidant vitamin supplementation (600 mg vitamin E, 250 mg vitamin C, and 20 mg -carotene daily) versus matching placebo	UK adults (aged 4080) with coronary disease, other occlusive arterial disease, or diabetes	Factorial plan double-blind UK

continued...

Trial	Treatments	Patients	Trials design and methods
PHS II beta carotene , 2003 [NCT00270647] n=2967/2989 follow-up: 8 years	400 IU of vitamin E every other day and 500 mg of vitamin C daily versus placebo	US male physicians enrolled, aged 50 years or older	Factorial plan double-blind
SUVIMAX , 2005 n=6481/6536 follow-up: 7.5 years	single daily capsule of combination of antioxydants: 120 mg of ascorbic acid, 30 mg of vitamin E, 6 mg of beta carotene, 100 g of selenium, and 20 mg of zinc versus matched placebo	women aged 35-60 years and men aged 45-60 years	Parallel groups double-blind France
WAVE (Waters) , 2002 n=212/211 follow-up: 2.8 years	400 IU of vitamin E twice daily plus 500 mg of vitamin C twice daily versus placebo	postmenopausal women with at least one 15% to 75% coronary stenosis	Factorial plan double-blind US, Canada

More details and results :

- antioxydants for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q131>
- antioxydants for cardiovascular prevention in diabetic patients at <http://www.trialresultscenter.org/go-Q232>
- antioxydants for cardiovascular prevention in primary prevention at <http://www.trialresultscenter.org/go-Q433>
- antioxydants for cardiovascular prevention in secondary prevention at <http://www.trialresultscenter.org/go-Q434>

References

PHS II (multivitamin), 2012:

Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, Schwartz M, Manson JE, Glynn RJ, Buring JE, Gaziano JM Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2012 Nov 7;308:1751-60 [23117775] [10.1001/jama.2012.14805](https://doi.org/10.1001/jama.2012.14805)

Sesso HD, Christen WG, Bubes V, Smith JP, Macfadyen J, Schwartz M, Manson JE, Glynn RJ, Buring JE, Gaziano JM Multivitamins in the Prevention of Cardiovascular Disease in Men: The Physicians' Health Study II Randomized Controlled Trial. JAMA 2012;308:1751-60 [23117775]

POPADAD (antioxydant), 2008:

Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008 Oct 16;337:a1840 [18927173]

HATS, 2001:

Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med* 2001;345:1583-92 [[11757504](#)]

MVP, 1997:

Tardif JC, Ct G, Lesprance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. *N Engl J Med* 1997;337:365-72 [[9241125](#)]

HPS antioxidant, 2002:

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002 Jul 6;360:23-33 [[12114037](#)]

PHS II beta carotene, 2003:

Christen WG, Gaziano JM, Hennekens CH Design of Physicians' Health Study II—a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. *Ann Epidemiol* 2000;10:125-34 [[10691066](#)]

Grodstein F, Kang JH, Glynn RJ, Cook NR, Gaziano JM A randomized trial of beta carotene supplementation and cognitive function in men: the Physicians' Health Study II. *Arch Intern Med* 2007;167:2184-90 [[17998490](#)]

Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. *JAMA* 2008;300:2123-33 [[18997197](#)]

SUVIMAX, 2005:

Herberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, Roussel AM, Favier A, Brianon S The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. *Arch Intern Med* 2004 Nov 22;164:2335-42 [[15557412](#)]

Herberg S, Preziosi P, Brianon S, Galan P, Triol I, Malvy D, Roussel AM, Favier A A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study—design, methods, and participant characteristics. *Supplementation en Vitamines et Minéraux Antioxydants. Control Clin Trials* 1998;19:336-51 [[9683310](#)]

Herberg S, Galan P, Preziosi P, Roussel AM, Arnaud J, Richard MJ, Malvy D, Paul-Dauphin A, Brianon S, Favier A Background and rationale behind the SU.VI.MAX Study, a prevention trial using nutritional doses of a combination of antioxidant vitamins and minerals to reduce cardiovascular diseases and cancers. *Supplementation en Vitamines et Minéraux Antioxydants Study. Int J Vitam Nutr Res* 1998;68:3-20 [[9503043](#)]

WAVE (Waters), 2002:

Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, Ouyang P, Thompson P, Tardif JC, Higginson L, Bittner V, Steffes M, Gordon DJ, Proschan M, Younes N, Verter JI Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. *JAMA* 2002 Nov 20;288:2432-40 [[12435256](#)]

2 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
combination vs placebo			

continued...

Trial	Treatments	Patients	Trials design and methods
POPADAD (antioxydant) , 2008 [ISRCTN53295293] n=640/636 follow-up:	antioxidant capsule containing (alpha-tocopherol 200 mg, ascorbic acid 100 mg, pyridoxine hydrochloride 25 mg, zinc sulphate 10 mg, nicotinamide 10 mg, lecithin 9.4 mg, and sodium selenite 0.8 mg) versus placebo	patients with diabetes mellitus and asymptomatic peripheral arterial disease	Factorial plan double blind Scotland

More details and results :

- antioxydants for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q231>

References

POPADAD (antioxydant), 2008:

Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008 Oct 16;337:a1840 [18927173]

3 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
combination vs placebo			
POPADAD (antioxydant) , 2008 [ISRCTN53295293] n=640/636 follow-up:	antioxidant capsule containing (alpha-tocopherol 200 mg, ascorbic acid 100 mg, pyridoxine hydrochloride 25 mg, zinc sulphate 10 mg, nicotinamide 10 mg, lecithin 9.4 mg, and sodium selenite 0.8 mg) versus placebo	patients with diabetes mellitus and asymptomatic peripheral arterial disease	Factorial plan double blind Scotland

More details and results :

- antioxydants for peripheral vascular diseases in all type of patients at <http://www.trialresultscenter.org/go-Q229>
- antioxydants for peripheral vascular diseases in diabetic patients at <http://www.trialresultscenter.org/go-Q230>

References

POPADAD (antioxydant), 2008:

Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. *BMJ* 2008 Oct 16;337:a1840 [[18927173](#)]

Entry terms: aminoglutethimide , Aminoglutethimide, Cytadren, Orimeten, tamoxifen, Tamoxifen, ICI-47699, ICI 47699, ICI47699, Nolvadex, Novaldex, Tamoxifen Citrate, Tomaxithen, Zitazonium, ICI-46474, ICI 46474, ICI46474, Soltamox